Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321112 | 0.91 | LMNA (0.38) | LMNASMN1; SMN2HPGDHSD17B10RAB9A | |
| SCHEMBL12814052 | 0.88 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2HPGDHSD17B10RAB9A | |
| SCHEMBL2169206 | 0.84 | LMNA (0.35) | LMNASMN1; SMN2HPGDHSD17B10RAB9A | |
| SCHEMBL16167268 | 0.83 | LMNA (0.41) | LMNASMN1; SMN2HPGDHSD17B10RAB9A | |
| SCHEMBL2208529 | 0.81 | LMNA (0.34) | LMNASMN1; SMN2HPGDHSD17B10RAB9A | |
| SCHEMBL906682 | 0.80 | ALDH1A1 (0.41) | LMNASMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL18958956 | 0.80 | LMNA (0.40) | LMNASMN1; SMN2HPGDHSD17B10RAB9A | |
| SCHEMBL15846573 | 0.80 | POLB (0.40) | LMNASMN1; SMN2HPGDRAB9AKMT2A | |
| SCHEMBL110223 | 0.80 | ALDH1A1 (0.46) | LMNASMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL2409030 | 0.79 | LMNA (0.35) | LMNASMN1; SMN2HPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794010-A1 | METHOD OF TREATMENT OF TUMORS THAT ARE RESISTANT TO EGFR THERAPIES BY EGFR ANTIBODY CYTOTOXIC AGENT CONJUGATE | ImmunoGen, Inc. (US) | 2014-10-29 | — | — | EP | claimed |
| WO-2014055842-A1 | PROCESS FOR PREPARING STABLE ANTIBODY MAYTANSINOID CONJUGATES | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2632490-A2 | NOVEL EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Immunogen, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2632947-A2 | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Immunogen, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2013078271-A1 | METHOD OF TREATMENT OF TUMORS THAT ARE RESISTANT TO EGFR THERAPIES BY EGFR ANTIBODY CYTOTOXIC AGENT CONJUGATE | IMMUNOGEN, INC. (US) | 2013-05-30 | — | — | WO | claimed |
| EP-2544719-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Immunogen, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| WO-2012058592-A2 | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-05-03 | — | — | WO | claimed |
| WO-2012058588-A2 | NOVEL EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-05-03 | — | — | WO | claimed |
| WO-2011112978-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| EP-4251648-A2 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| EP-4142799-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022112942-A2 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3980423-A1 | 5H-PYRROLO[3,2-D]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3962951-A1 | ANTI-BCMA ANTIBODY CONJUGATES | Sutro Biopharma, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2006104677-A2 | ANTIBODIES THAT BIND OV064 AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006061259-A2 | CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061258-A2 | CYTOTOXIC AGENTS COMPRISING NEW TAXANES | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
| EP-1390370-A4 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1390370-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | Immunogen, Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002098883-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN, INC. (US) | 2002-12-12 | — | — | WO | disclosed |